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Risk factors for invasive pulmonary aspergillosis
(IPA) after kidney transplantation have been poorly
explored. We performed a multinational case–control
study that included 51 kidney transplant (KT) recipi-
ents diagnosed with early (first 180 posttransplant
days) IPA at 19 institutions between 2000 and 2013.
Control recipients were matched (1:1 ratio) by center
and date of transplantation. Overall mortality among
cases was 60.8%, and 25.0% of living recipients expe-
rienced graft loss. Pretransplant diagnosis of chronic
pulmonary obstructive disease (COPD; odds ratio
[OR]: 9.96; 95% confidence interval [CI]: 1.09–90.58;
p = 0.041) and delayed graft function (OR: 3.40; 95%
CI: 1.08–10.73; p = 0.037) were identified as indepen-
dent risk factors for IPA among those variables
already available in the immediate peritransplant
period. The development of bloodstream infection
(OR: 18.76; 95% CI: 1.04–339.37; p = 0.047) and acute
graft rejection (OR: 40.73, 95% CI: 3.63–456.98;
p = 0.003) within the 3 mo prior to the diagnosis of
IPA acted as risk factors during the subsequent per-
iod. In conclusion, pretransplant COPD, impaired
graft function and the occurrence of serious post-
transplant infections may be useful to identify KT
recipients at the highest risk of early IPA. Future
studies should explore the potential benefit of anti-
mold prophylaxis in this group.
Abbreviations: BAL, bronchoalveolar lavage; BSI,
bloodstream infection; CI, confidence interval; CMV,
cytomegalovirus; CoNS, coagulase-negative staphylo-
cocci; COPD, chronic obstructive pulmonary disease;
EBNA, Epstein–Barr virus nuclear antigen; eGFR, esti-
mated GFR; EORTC/MSG, European Organization for
Research and Treatment of Cancer/Invasive Fungal
Infections Cooperative Group and the National Insti-
tute of Allergy and Infectious Diseases Mycoses Study
Group; GM, galactomannan; HBc, hepatitis B core
antigen; HCV, hepatitis C virus; ICU, intensive care
unit; IPA, invasive pulmonary aspergillosis; IQR,
interquartile range; KT, kidney transplant; OR, odds
ratio; ROC, receiver operating characteristic; SD, standard
deviation; SOT, solid organ transplant; VIF, variance
inflation factor
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Introduction
Patients who have undergone kidney transplant (KT)
require life-long immunosuppressive treatment to pre-
vent graft rejection. This circumstance increases their
risk for developing severe opportunistic infections, includ-
ing invasive pulmonary aspergillosis (IPA) (1,2). Of note,
mortality rates ranging from 56% to 67% have been
reported among KT recipients diagnosed with this com-
plication (3,4).
The incidence rate of IPA after KT is lower than those
observed for other solid organ transplant (SOT) popula-
tions. A multicenter survey in France revealed an inci-
dence of 0.4% among KT recipients in comparison to
1.3% and 1.9% after heart and liver transplantation,
respectively (3). Similar figures have been reported in
other large studies, with incidence rates <0.5% (5,6). In
view of such low incidence, the universal use of antimold
prophylaxis in KT recipients is not feasible or advisable
(2,7). Nevertheless, it should be noted that KT repre-
sents, by far, the most frequently performed transplant
procedure worldwide. Consequently, KT recipients suffer
from the highest burden of posttransplant IPA events in
absolute terms, exceeded only by lung transplant recipi-
ents (5,8–10); for example, 47 cases of IPA in KT recipi-
ents were identified between 2001 and 2006 in the
Transplant-Associated Infection Surveillance Network
(TRANSNET) database, compared with only 42 and 23
cases among liver and heart transplant recipients,
respectively (8).
Notwithstanding this fact and the dismal prognosis of
this condition, our current knowledge about IPA after KT
is limited mainly to single case reports, small case series
(11), studies covering the overall SOT population (in
which KT recipients are underrepresented) (9,10,12), or
studies including invasive fungal diseases caused by both
molds and yeasts (13–15). To date, only one single-
center case–control study has been specifically aimed at
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ascertaining the conditions leading to the development
of IPA in KT recipients (16). The authors identified
leukopenia and a longer duration of pretransplant renal
replacement therapy as risk factors for early IPA
(i.e. diagnosed within the first 3 mo), although only 15
cases were included in the multivariable model.
Most cases of IPA in SOT recipients are diagnosed dur-
ing the first months following transplantation, when the
overall amount of immunosuppression is higher (6,8);
therefore, preventive efforts should be optimized
throughout that period. The aim of our study was to
assess the predisposing factors for the development of
early IPA in a large representative population of KT
recipients.
Materials and Methods
Study design
The present study was developed in 29 hospitals from 10 different coun-
tries (Spain, United States, Switzerland, Belgium, Brazil, Portugal, France,
Mexico, Argentina, and United Kingdom). The Swiss Transplant Cohort
Study contributed with the joint experience from six transplant centers in
Switzerland, as detailed elsewhere (17,18). Participating centers were
invited to include cases of early IPA (i.e. within the first 180 days after
transplantation) diagnosed in KT recipients between January 1, 2000, and
December 31, 2013 (IPA cases). Patients who underwent transplantation
immediately before or after the index case at each center and with no
evidence of IPA throughout the posttransplant period were selected as
controls at a 1:1 ratio (control group). With matching by institution and
date of transplantation, we attempted to control for potential imbalances
in terms of posttransplant clinical management and institutional protocols
across different periods. To be eligible, control participants must have
survived at least until the time of diagnosis of IPA in the corresponding
index case. To assess the impact of posttransplant risk factors (i.e. occur-
rence of acute graft rejection) on the occurrence of early IPA, control par-
ticipants were assigned a “pseudo–date of diagnosis” to match their
case with the aim of ensuring comparable periods of risk exposure in
both groups. The date of diagnosis for IPA cases was defined as the cal-
endar day on which the first clinical sample yielding Aspergillus spp. or
the first detection of positive galactomannan (GM) assay was obtained.
For cases in which the diagnosis of IPA was established only after
autopsy, the date of death was used as the date of diagnosis.
The study was developed with the institutional support of the Spanish
Network Research of Infectious Diseases and the Group for the Study of
Infection in Transplant Recipients of the Spanish Society of Clinical Micro-
biology and Infectious Diseases. The study protocol was approved by the
ethics committee of the coordinating center and by the individual partici-
pating centers, as required.
Study definitions
IPA was defined according to the revised criteria proposed in 2008 by
the European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the National Institute
of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG)
Consensus Group (19). We included IPA cases that fulfilled modified
EORTC/MSG definitions for probable or proven diagnosis categories.
Cases were deemed proven when the diagnosis was established by the
visualization of molds in a lung biopsy (or autopsy) with the simultaneous
recovery of Aspergillus spp. in culture from lung tissue, sputum, bron-
choalveolar lavage (BAL) or bronchial brush samples. Cases were catego-
rized as probable IPA on the basis of the simultaneous presence of at
least one host factor plus a radiological criterion plus a mycological crite-
rion. The host factor was assumed to be the receipt of KT under chronic
immunosuppressive therapy. The modified radiological criteria included
the demonstration of not only dense, well-circumscribed lesions (with or
without halo sign or cavitation) but also other lung infiltrates compatible
with infection. This latter criterion responds to previous clinical experi-
ences suggesting that IPA in SOT recipients may be accompanied by
lung infiltrates (i.e. peribronchial consolidation or tree-in-bud pattern) that
differ from the typical signs observed in hematological patients (20). The
microbiological criteria included the recovery of Aspergillus spp. in culture
from sputum, BAL or bronchial brush samples and/or a positive GM
assay (cutoff value of 0.5 optical densities in plasma or serum specimens
and 1.0 in BAL specimens). All IPA cases were independently reviewed
by an infectious disease specialist at the coordinating center who
rejected those cases that did not fulfill the above-mentioned criteria. Mor-
tality was considered attributable to IPA when the patient died with
microbiological, histological or clinical evidence of active IPA (proven or
probable) and other potential causes of death were reasonably excluded
by the attending physician (21). Cytomegalovirus (CMV) disease included
viral syndrome (defined by the demonstration of CMV infection by pp65
antigenemia plus one or more of the following: fever, new-onset or
increased malaise, leukopenia, atypical lymphocytosis, thrombocytopenia,
or elevation of alanine aminotransferase or aspartate aminotransferase
higher than two times the upper limit of normal) and probable or defini-
tive end-organ disease, as defined previously (22). The diagnosis of pneu-
monia included community-acquired, hospital-acquired, health care–
associated and ventilator-associated forms. Only laboratory-confirmed
cases of influenza or other respiratory viruses were analyzed. Blood-
stream infection (BSI) was defined as the presence of one microorganism
or more in one blood culture along with clinical evidence of infection. For
those microorganisms usually considered skin contaminants (i.e. coagu-
lase-negative staphylococci [CoNS]), two consecutive positive cultures
were required. Delayed graft function denoted the requirement for dialy-
sis within the first 2 weeks after transplantation. Acute graft rejection
was diagnosed by histological examination if possible or by response to
empirical antirejection treatment (23). Estimated GFR (eGFR) was
assessed using the four-variable MDRD equation (24).
Statistical analysis
Continuous variables were summarized using the mean plus or minus
standard deviation or the median with interquartile range (IQR), whereas
categorical variables were summarized using absolute counts and per-
centages. Categorical variables were compared using the McNemar test,
whereas the Student t-test for repeated measures or the Wilcoxon
signed rank test was applied for continuous variables. Conditional logistic
regression was used to identify independent risk factors for early IPA.
Those variables found to be significant (p ≤ 0.05) in the univariate analysis
were included into the multivariable models in a backward stepwise fash-
ion. Continuous variables (i.e. total lymphocyte count) were entered after
dichotomization by the optimal cutoff values for distinguishing cases from
controls on the basis of the Youden index or J statistic (J = sensitivity +
specificity  1) (25). Collinearity among explanatory variables was
assessed using variance inflation factors (VIFs). VIF values >3 suggest
the presence of significant collinearity. It is conventionally assumed that
regression models should be used with a minimum of 10 events per
explanatory variable to avoid model overfitting, unreliable confidence
interval coverage and convergence problems because this ratio declines
below such a threshold. In addition, we sought to identify a set of predic-
tive criteria for the development of early IPA that would be easily usable
by clinicians to identify a subgroup of high-risk KT recipients during either
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the peritransplant period or throughout the following months. Conse-
quently, we performed two separate models: The first included only
those variables already available at the time of transplantation or within
the first 2 weeks (immediate peritransplant period), whereas the second
model was constructed on those events that occurred during the subse-
quent period (mostly posttransplant complications) that had been identi-
fied at the univariate level as risk factors for the development of early
IPA. The goodness of fit of both models was evaluated by the Hosmer-
Lemeshow test. Results are given as odds ratios (ORs) with 95% confi-
dence intervals (CIs). Given the long time frame of the study, an “era
effect” was forced into the models by dividing the recruitment period
into two parts (cases diagnosed in the period 2000–2009 and in 2010–
2013).
In addition, we attempted to obtain an explanatory risk score based on
the variables selected in the regression models by assigning a point value
corresponding to the b-coefficient of that variable rounded to the nearest
whole number. Summation of the points resulted in a weighted score
that was assigned to each case and control. The accuracy of such score
was assessed by means of the area under receiver operating characteris-
tic (ROC) curve.
All significance tests were two-tailed. Statistical analysis was performed
using SPSS version 15.0 (IBM Corp, Armonk, NY).
Results
We included 51 early IPA cases (14 proven and 37 proba-
ble) and 51 controls from 19 institutions located in Eur-
ope and the Americas (16 and 3 centers, respectively).
Approximately half of the IPA cases (25 of 51) were diag-
nosed between 2010 and 2013. The mean number of
cases included from each center was 2.7 (range: 1–7).
The median interval between transplantation and diagno-
sis was 91 days (IQR: 65–116 days), with 4 (7.8%), 7
(13.7%) and 14 (27.5%) cases occurring in the first, sec-
ond and third posttransplant months, respectively (Fig-
ure 1). Overall mortality for IPA cases was 60.8% (31 of
51) and occurred at a median of 15 days (IQR: 6–59
days) from diagnosis, whereas the IPA-attributable mor-
tality was 45.1% (23 of 51). Among living recipients,
25.0% (5 of 20) experienced definitive graft failure requir-
ing return to permanent dialysis.
Table 1 details the demographics and pretransplant fac-
tors of cases and their control counterparts. Cases had a
higher baseline prevalence of chronic obstructive pul-
monary disease (COPD) and were more likely to be
receiving chronic dialysis at the time of transplantation.
Donor- and transplant-related and posttransplant variables
are shown in Table 2. In comparison to controls, cases
were more likely to suffer from delayed graft function; to
have been diagnosed with pneumonia, CMV disease, BSI
or acute graft rejection within the 3 mo prior to the diag-
nosis of early IPA; and to have required admission to the
intensive care unit for at least 72 h during that period.
The episodes of BSI were caused by CoNS (four cases),
Enterobacteriaceae (three cases), Pseudomonas
aeruginosa (three cases), Staphylococcus aureus and
Enterococcus spp. (two cases each), and Nocardia (one
case). In contrast, controls were more likely to have
received a graft from a living donor. With regard to graft
function, cases had consistently lower eGFR at the dif-
ferent time points preceding the diagnosis of IPA com-
pared with controls. The total lymphocyte count at day 7
after transplantation was significantly lower in cases than
in controls (Figure 2). The optimal cutoff value (i.e. value
with the highest Youden index to distinguish cases and
controls) for this variable was 1.75 9 103 cells/lL.
As detailed earlier in the Materials and Methods, we
performed two separate conditional logistic regression
models. There was no significant collinearity between
the explanatory variables included in either of the mod-
els, with all VIF values <1.5 (data not shown).
The first explanatory model was limited to those vari-
ables that were already available at the time of transplan-
tation or within the first 2 weeks (immediate
peritransplant period). Pretransplant diagnosis of COPD
(OR: 9.96; 95% CI: 1.09–90.58; p = 0.041) and delayed
graft function (OR: 3.40; 95% CI: 1.08–10.73; p = 0.037)
were independent risk factors for the occurrence of early
IPA (Table 3). The Hosmer-Lemeshow test showed a
good fit for the model (p = 0.789).
The second model included as explanatory variables
those events occurring beyond the immediate posttrans-
plant period (Table 4). The development of BSI (OR:
18.76; 95% CI: 1.04–339.37; p = 0.047) and acute graft
rejection (OR: 40.73, 95% CI: 3.63–456.98; p = 0.003)
within the 3 mo preceding the diagnosis of IPA (or the
analogous pseudo–date of diagnosis in controls) were
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Figure 1: Temporal distribution of cases of early invasive
pulmonary aspergillosis occurring according to posttrans-
plant month of diagnosis.
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identified as independent risk factors for early IPA. The
Hosmer-Lemeshow test again demonstrated a good fit
for the model (p = 0.910). These results remained
unchanged when the era of diagnosis (2000–2009 or
2010–2013) was entered in both models (data not
shown).
Finally, in an attempt to gain some preliminary insight
into the potential feasibility of individualizing the risk of
early IPA on the basis of these criteria, we constructed a
score by assigning the following point values according
to the b-coefficients of each factor: acute graft rejection
(4 points), prior occurrence of BSI (3 points), pretrans-
plant diagnosis of COPD (2 points) and delayed graft
function (1 point). As expected, the resulting weighted
risk scores differed significantly between cases and con-
trols (median points: 4 [IQR: 0–1] and 0 [IQR: 3–5],
respectively; p < 0.001). The area under the ROC curve
for distinguishing cases from controls was 0.89 (95% CI:
0.83–0.96). As shown in Table 5, only 9.8% (4 of 41) of
patients that eventually developed IPA (i.e. cases) were
given 0 points in the score compared with 90.2% (37 of
41) of controls. In contrast, the presence of scores of
4–5 or ≥6 points would allow correct categorization
of IPA cases in 79.3% (23 of 29) and 100.0% (11 of 11)
of patients, respectively.
Discussion
Early IPA represents a devastating complication among
KT recipients. The all-cause mortality rate in the present
cohort was >60%, with most of the deaths directly attribu-
table to aspergillosis. The above-mentioned single-center
Table 1: Comparison of demographics and pretransplant variables between kidney transplant recipients with and without IPA within
the first 180 days after transplantation
Variable IPA group (n = 51) Control group (n = 51) p-value1
Age, years, mean  SD 57.3  15.6 54.4  14.5 0.211
Sex, male, n (%) 37 (72.5) 32 (62.7) 0.424
Pretransplant conditions, n (%)
Diabetes mellitus 12 (23.5) 15 (29.4) 0.629
Chronic obstructive pulmonary disease 8 (15.7) 1 (2.0) 0.039
Pretransplant corticosteroid therapy, n (%) 6 (11.8) 7 (13.7) 1.000
ICU admission within 3 mo before transplantation, n (%)2 0 (0.0) 1 (2.2) 1.000
BMI at transplantation, kg/m2, mean  SD3 25.9  5.6 25.2  4.7 0.421
Previous kidney transplantation, n (%) 8 (15.7) 4 (7.8) 0.344
Underlying end-stage renal disease, n (%)
Glomerulonephritis 12 (23.5) 11 (21.6) 1.000
Diabetic nephropathy 8 (15.7) 8 (15.7) 1.000
Nephroangiosclerosis 6 (11.8) 6 (11.8) 1.000
Polycystosis 9 (17.6) 6 (11.8) 0.581
Chronic interstitial nephropathy 3 (5.9) 5 (9.8) 0.727
Lupus nephropathy 0 (0.0) 5 (9.8) 0.063
Reflux nephropathy 1 (2.0) 0 (0.0) 1.000
Unknown 5 (9.8) 5 (9.8) 1.000
Other 8 (15.7) 6 (11.8) 0.791
Pretransplant serostatus, n (%)
Hepatitis C virus4 5 (10.0) 1 (1.9) 0.125
Hepatitis B virus (anti-HBc)5 7 (15.2) 4 (9.3) 0.375
Hepatitis B virus (surface antigen)4 1 (2.0) 1 (1.9) 1.000
Epstein–Barr virus (anti-EBNA)6 40 (88.9) 39 (86.7) 1.000
CMV7 41 (82.0) 43 (91.5) 1.000
Renal replacement therapy, n (%)7 0.008
No (preemptive transplantation) 0 (0.0) 8 (17.0)
Pretransplant maintenance dialysis 50 (100.0) 39 (82.9)
Duration, mo, median (IQR) 30.0 (17.0–57.8) 24.0 (12.0–58.0) 0.152
CMV, cytomegalovirus; EBNA, Epstein–Barr virus nuclear antigen; HBc, hepatitis B core antigen; ICU, intensive care unit; IPA, invasive
pulmonary aspergillosis; IQR, interquartile range; SD, standard deviation.
1Significant p-values (<0.05) are expressed in bold type.
2Data available for 48 cases and 46 controls.
3Data available for 34 cases and 34 controls.
4Data available for 50 cases and 51 controls.
5Data available for 46 cases and 43 controls.
6Data available for 45 cases and 45 controls.
7Data available for 50 cases and 47 controls.
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study (which analyzed both early and late forms of IPA)
found an overall mortality rate of 39% (16). These results
highlight the imperative need to identify risk factors that
could define a subgroup of KT recipients who would
benefit from targeted preventive strategies, and our
study may provide preliminary evidence on this point.
We decided to focus on patients developing early forms
of IPA, for two reasons. First, almost half of the
episodes of IPA in this population occur within the first
3–6 mo after transplantation (45% and 56% of the cases
included in our multinational study [data not shown] and
in the study by Heylen et al (16), respectively); ultimately,
this would lead to prescription of antimold prophylaxis
for well-delimitated time periods. Second, KT recipients
are more closely followed during this early posttransplant
period, allowing more accurate identification of predis-
posing conditions.
The presence of graft dysfunction, reflected by the
requirement for dialysis within the first weeks following
transplantation and by the development of acute rejec-
tion, was identified in our experience as a potential risk
factor for early IPA. Apart from its direct impact on
immune status, the occurrence of delayed graft function
also could be acting as a kind of “clinical surrogate” that
summarized different conditions (i.e. longer hospital stay,
urinary tract complications or higher transfusion require-
ments) that exert a deleterious effect overall on the
host’s susceptibility to infection and that may remain hid-
den in a single-condition, deterministic model. Acute
graft rejection has been previously reported to increase
the incidence of invasive fungal disease after KT (13),
and graft failure has been found to be a risk factor for
IPA in SOT recipients (6,12,26,27). Of note, we noted
that the pretransplant diagnosis of COPD and the occur-
rence of posttransplant pneumonia also increased the
risk of early IPA, suggesting the role of previous injury to
lung parenchyma as a sort of breeding ground for Asper-
gillus. The diagnosis of pneumonia preceding the onset
of IPA has been reported in previous noncomparative
studies (11,28). Recent publications have underscored
the importance of COPD as a predisposing risk factor for
aspergillosis (29,30), and it has been demonstrated that
alveolar macrophages in patients with COPD exhibit
impairment in their phagocytic function, suggesting the
existence of a compartmentalized immunological defect
(31).
Cases developing early IPA were more likely to have
been diagnosed previously with BSI and CMV disease,
Table 2: Comparison of donor- and transplant-related factors and posttransplant complications
Variable IPA group (n = 51) Control group (n = 51) p-value1
Age of donor, years, mean  SD 56.5  14.0 51.1  16.0 0.060
Living donor, n (%) 5 (9.8) 14 (27.5) 0.022
Double kidney transplantation, n (%) 0 (0.0) 2 (4.1) 0.500
Induction therapy, n (%)
None 14 (27.5) 11 (21.6) 0.581
Anti-CD25 (basiliximab or daclizumab) 23 (45.1) 29 (56.9) 0.263
Anti–thymocyte globulin 13 (25.5) 9 (17.6) 0.454
Primary immunosuppression scheme including, n (%)
Steroids 48 (94.1) 48 (94.1) 1.000
Tacrolimus 28 (54.9) 31 (60.8) 0.607
Cyclosporine 15 (29.4) 13 (26.0) 0.774
MMF/MPA 47 (92.2) 47 (92.2) 1.000
Azathioprine 0 (0.0) 1 (2.0) 1.000
mTOR inhibitor 1 (2.0) 1 (2.0) 1.000
Length of hospital admission for transplantation, days, median (IQR)2 19.5 (14.3–36.5) 10.0 (7.3–15.0) <0.001
Delayed graft function, n (%) 22 (43.1) 8 (15.7) 0.007
Surgical reintervention, n (%) 8 (15.7) 3 (5.9) 0.065
Posttransplant events in the three preceding months, n (%)3
Pneumonia or laboratory-confirmed viral respiratory tract infection 15 (29.4) 1 (2.0) 0.001
CMV disease 11 (21.6) 2 (3.9) 0.012
Bloodstream infection 14 (27.5) 1 (2.0) 0.001
ICU admission for ≥72 h 9 (17.6) 1 (2.0) 0.021
Invasive mechanical ventilation 6 (11.8) 1 (2.0) 0.125
Acute graft rejection 32 (62.7) 5 (9.8) <0.001
Episode treated with steroid boluses 25 (49.0) 3 (5.9) <0.001
CMV, cytomegalovirus; ICU, intensive care unit; IPA, invasive pulmonary aspergillosis; IQR, interquartile range; MMF/MPA, mofetil
mycophenolate/mycophenolate acid; mTOR, mammalian target of rapamycin; SD, standard deviation.
1Significant p-values (<0.05) are expressed in bold type.
2Data available for 48 cases and 46 controls.
3Events occurring in the 3 mo previous to the date of diagnosis of IPA for cases or the analogous “pseudo–date of diagnosis” for their
corresponding controls.
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although only the former association remained in the
conditional logistic regression model. The link between
bacterial infection and early IPA was already described in
a multicenter study that included mainly liver transplant
recipients (6). It could be speculated that the develop-
ment of posttransplant BSI might represent a proxy for
prolonged hospital stay, longer antibiotic exposure and
higher rates of invasive procedures, which in turn would
identify a subgroup of recipients prone to a higher bur-
den of systemic inflammation, malnutrition and impair-
ment of cell-mediated immunity. Interestingly, the
prevalence of hepatitis C virus (HCV) infection was five
times higher among cases than controls, although this
difference did not attain statistical significance because
of the low numbers included in each group. Previous
studies suggested that chronic HCV infection may
increase the incidence of severe infection in KT recipi-
ents (32). In contrast, CMV is known to cause a number
of indirect effects related to its immunomodulatory
mechanisms that lead to nonspecific inhibition of the
cell-mediated and humoral immune responses (33). The
role of CMV infection as a risk factor for IPA has been
well established in different SOT populations (6,15,34). In
addition to the biological plausibility of this association, it
should not be ruled out that the diagnosis of CMV dis-
ease may simply act as a surrogate marker for immuno-
suppression, as suggested by the lack of statistical
significance when other posttransplant events (e.g. acute
rejection) were adjusted for in our multivariable model.
Total lymphocyte count at day 7 after transplantation
was significantly lower in cases than in controls in the
univariate but not in the multivariable analysis. This
parameter may be considered an affordable approach to
the posttransplant cell-mediated immunity status, and
previous studies have demonstrated the value of
lymphopenia—particularly at the expense of CD4+ and
CD8+ T cell subpopulations—for predicting the develop-
ment of opportunistic infections in KT recipients (35,36).
The present study has a number of strengths, including
stringent application of uniform diagnostic criteria, com-
prehensive assessment of a large number of explanatory
variables, a multicenter design (that ensures appropriate
external validity) and biological plausibility of the associa-
tions found. By using two separate multivariable models,
we established different sets of predisposing factors that
may be easily identified by clinicians and that define two
different risk profiles. The first risk profile includes those
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Figure 2: Comparison between kidney transplant recipients with
and without early IPA in terms of (A) graft function, (B) leukocyte
count, and (C) total lymphocyte count, at different time points.
Only values determined before the date of diagnosis of IPA in
cases (or the analogous “pseudo–date of diagnosis” in controls)
were analyzed (points represent the mean values, and error bars
denote the standard deviations). Student t-test for paired data:
*p < 0.001; **p < 0.05; ***p < 0.01. eGFR, estimated GFR; IPA,
invasive pulmonary aspergillosis.
Table 3: Univariate and multivariable analyses (conditional logistic regression) of risk factors present at the immediate peritransplant
period predicting the development of early IPA
Peritransplant factors
Univariate analysis Multivariable analysis1
OR 95% CI p-value ß-coefficient OR 95% CI p-value
Pretransplant diagnosis of COPD 8.00 1.00–63.96 0.050 2.29 9.96 1.09–90.58 0.041
Pretransplant dialysis 7.00 0.96–56.89 0.069 – – – –
Living donor 0.18 0.04–0.82 0.027 – – – –
Delayed graft function 3.80 1.42–10.18 0.008 1.22 3.40 1.08–10.73 0.037
CI, confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio.
1Hosmer–Lemeshow p-value = 0.789.
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KT recipients who already face an increased risk of IPA
from the time of transplantation because of their pre-
transplant comorbidities or impaired graft function. The
second risk profile takes into account the occurrence of
different events during the first posttransplant months
that modulate individual susceptibility to IPA, such as
graft rejection. On the basis of these variables, we aimed
to construct a single weighted risk score, although it is
far from our intention to encourage its application to the
clinical decision-making process.
Our study also has some limitations. Despite the collabo-
rative effort to include a large number of early IPA cases,
the effective sample size was low, and results are
offered with wide CIs (e.g. only one control participant
had pretransplant COPD). The choice of matching each
case with a single control was made mainly on practical
grounds to optimize the data-collection effort, although
this design might have compromised the statistical
power. We can only infer potential associations rather
than demonstrate direct causality in the pathogenesis of
posttransplant IPA because the impact of unmeasured
confounders cannot be excluded. The proposed score
must be regarded as merely explanatory rather than pre-
dictive and should be tested in an appropriately sized vali-
dation cohort. In addition, the combination of variables
derived from two different models may have inflated
ORs. A nonnegligible proportion of cases (7.8% [4 of 51])
had a score of 0 points, a proportion that might be still
considered excessive to determine individualized use of
antimold prophylaxis. Moreover, it should be stressed
that because the case–control design of our study did
not allow the calculation of incidence rates of posttrans-
plant IPA across participating centers, we were not able
to formally estimate the positive and negative predictive
values of the score. The attribution of direct causality
between the occurrence of posttransplant IPA and death
should be made with caution because of the retrospective
nature of the research. Most analyzed cases were
probable forms of IPA, according to the EORTC/MSG
criteria. Finally, the long case-inclusion period and the
considerable number of participating centers led to
some degree of heterogeneity in the immunosuppressive
regimens and the practices of posttransplant care. Never-
theless, because of the rarity of early IPA in the specific
population of KT recipients and the difficulty of obtaining
a large series from a single institution, we think this
methodological approach is a valid way to clarify critical
aspects of this life-threatening complication.
Different regimens of antifungal prophylaxis have been
used in heart (34) and liver transplantation (37). Notwith-
standing its exploratory and hypothesis-generating nat-
ure, our study may entail both experimental and clinical
implications, although, as mentioned, its case–control
design prevents estimation of the number of patients
that should be exposed to a prophylaxis to prevent a sin-
gle case of IPA. Ultimately, the potential usefulness of
preventive strategies based on tapered immunosuppres-
sion, close clinical and diagnostic follow-up, and targeted
administration of antimold prophylaxis in KT recipients
Table 4: Univariate and multivariable analyses (conditional logistic regression) of risk factors occurring during the posttransplant period
Posttransplant events
occurring before IPA diagnosis2
Univariate analysis Multivariable analysis1
OR 95% CI p-value ß-coefficient OR 95% CI p-value
ICU admission for ≥72 h 9.00 1.14–71.04 0.037 – – – –
Total lymphocyte count <1.75 9 103
cells/lL at day 7 after transplant3
10.00 1.28–78.12 0.028 – – – –
Pneumonia or laboratory-confirmed
viral respiratory tract infection
15.00 1.98–113.56 0.009 – – – –
CMV disease 10.00 1.28–78.12 0.028 – – – –
BSI 14.00 1.84–106.47 0.011 2.93 18.76 1.04–339.37 0.047
Acute graft rejection 28.00 3.81–205.79 0.001 3.70 40.73 3.63–456.98 0.003
BSI, bloodstream infection; CI, confidence interval; CMV, cytomegalovirus; ICU, intensive care unit; IPA, invasive pulmonary aspergillo-
sis; OR, odds ratio.
1Hosmer–Lemeshow test, p = 0.910.
2Events occurring in the 3 mo previous to the date of diagnosis of IPA for cases or the analogous “pseudo–date of diagnosis” for their
corresponding controls.
3Only values determined before the date of diagnosis of IPA in cases (or the analogous pseudo–date of diagnosis in controls) were
taken into account.
Table 5: Distribution of the risk score values between IPA
cases and their corresponding controls
Risk score1
Overall
(n = 102)
IPA group
(n = 51)
Control group
(n = 51)
0 41 4 (9.8) 37 (90.2)
1–3 21 13 (61.9) 8 (38.1)
4–5 29 23 (79.3) 6 (20.7)
≥6 11 11 (100.0) 0 (0.0)
IPA, invasive pulmonary aspergillosis.
1Includes the following variables: pretransplant chronic obstruc-
tive pulmonary disease (2 points), delayed graft function (1
point), posttransplant bloodstream infection (3 points), and acute
graft rejection (4 points).
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with the risk factors identified in the present study
remains to be demonstrated.
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